Zenas BioPharma Inks $2 Billion+ Licensing Deal With InnoCare for Autoimmune Drug Candidates

Zenas BioPharma; InnoCare Pharma; autoimmune diseases; multiple sclerosis; BTK inhibitor; orelabrtuinib; licensing deal; clinical trials; IL-17 inhibitor; TYK2 inhibitor

Sanofi Challenges Novartis’ Dominance with Clinically Meaningful Pancreatic Tumor Data from AlphaMedix Phase II Trial

Sanofi; Novartis; radiopharma; AlphaMedix; Orano Med; gastroenteropancreatic neuroendocrine tumors; GEP-NETs; radioligand therapy; Phase II clinical trial; progression-free survival; overall survival; safety profile

Boehringer Ingelheim Breaks Decade-Long Drought with FDA Approval of Jascayd for Idiopathic Pulmonary Fibrosis

Boehringer Ingelheim; Jascayd; nerandomilast; FDA approval; idiopathic pulmonary fibrosis; IPF; lung scarring; first new treatment; chronic lung disease

CDC Updates COVID-19 and Chickenpox Vaccine Guidance Based on ACIP Recommendations

CDC; COVID-19 vaccine; chickenpox vaccine; ACIP; individual-based decision-making; MMRV; varicella; immunization schedule; febrile seizure

AstraZeneca and Daiichi Sankyo Report Landmark Results for Datroway in Triple-Negative Breast Cancer

Datroway; Datopotamab deruxtecan; triple-negative breast cancer; ADC; AstraZeneca; Daiichi Sankyo; clinical trial; overall survival; chemotherapy; TROP2; phase 3 trial; immunotherapy; TROPION-Breast02

FDA Launches Pilot Program to Prioritize U.S. Generic Drug Manufacturing and Testing

FDA; pilot program; generic drugs; ANDA prioritization; domestic manufacturing; bioequivalence testing; U.S. pharmaceutical supply chain; drug approval; supply chain resilience

Recent Trends in Biomarker Testing for NSCLC: Maximizing Real-World Survival

NSCLC; biomarker testing; overall survival; PD-L1; EGFR; ALK; next-generation sequencing; liquid biopsy; precision medicine; real-world data